Reported Late Wednesday, HUTCHMED's Tazemetostat For Relapsed/Refractory Follicular Lymphoma Secures NDA Acceptance And Priority Review In China
Reported Late Wednesday, HUTCHMED's Tazemetostat For Relapsed/Refractory Follicular Lymphoma Secures NDA Acceptance And Priority Review In China
據週三晚報導,福修康美藥業的Tazemetostat用於復發/難治性濾泡性淋巴瘤已獲中國新藥申請受理並獲得優先審評。
Reported Late Wednesday, HUTCHMED's Tazemetostat For Relapsed/Refractory Follicular Lymphoma Secures NDA Acceptance And Priority Review In China
據週三晚報導,福修康美藥業的Tazemetostat用於復發/難治性濾泡性淋巴瘤已獲中國新藥申請受理並獲得優先審評。